ArticleHeliyon2024
MobileNet-V2 /IFHO model for Accurate Detection of early-stage diabetic retinopathy.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Machine learning models for risk prediction of diabetic retinopathy in Fujian eye study.Frontiers in endocrinology · 2026Article
- Efficient fusion transformer model for accurate classification of eye diseases.Scientific reports · 2025Article
- MITD-Net: Markov image-based threat detection network.Scientific reports · 2025Article
- Two-Stage Hierarchical Pruning (THP-CNN) of Convolutional Neural Networks for Rapid Pathogenic Bacterial Detection Using High-Resolution Colony Images in Intensive Care Units.Diagnostics (Basel, Switzerland) · 2025Article
- Quantitative Evaluation of Tendon Gliding Sounds and Their Classification Using Deep Learning Models.Cureus · 2025Article
- Optimizing breast cancer ultrasound diagnosis: a comparative study of AI model performance and image resolution.Frontiers in oncology · 2025Article
- A comparative study of machine learning models for automated detection and classification of retinal diseases in Ghana.PloS one · 2025Article
- Article
Corrections and comments
- Retraction · 2026-03-17Author Unresponsive · Concerns/Issues about Referencing/Attributions · Investigation by Journal/Publisher · Unreliable Results and/or Conclusions ·
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy is a serious eye disease that may lead to loss of vision if it is not treated. Early detection is crucial in preventing further vision impairment and enabling timely interventions. Despite notable advancements in AI-based methods for detecting diabetic retinopathy, researchers are still striving to enhance the efficiency of these techniques. Therefore, obtaining an efficient technique in this field is essential. In this research, a new strategy has been proposed to improve the detection of diabetic retinopathy by increasing the accuracy of diagnosis and identifying cases in the initial stages. To achieve this, it has been proposed to integrate the MobileNet-V2 deep learning-based neural network with Improved Fire Hawk Optimizer (IFHO). The MobileNet-V2 network has been renowned for its efficiency and accuracy in image classification tasks, making it a suitable candidate for diabetic retinopathy detection. By combining it with the IFHO, the feature selection process has been optimized, which is essential for identifying relevant patterns and abnormalities related to diabetic retinopathy. The Diabetic Retinopathy 2015 dataset has been used to evaluate the effectiveness of the MobileNet-V2/IFHO model. The study results indicate that the DRMNV2/IFHO model consistently outperforms other methods in terms of precision, accuracy, and recall. Specifically, the model achieves an average precision of 97.521 %, accuracy of 96.986 %, and recall of 98.543 %. Moreover, when compared to advanced techniques, the DRMNV2/IFHO model demonstrates superior performance in specificity, F1-score, and AUC, with average values of 97.233 %, 93.8 %, and 0.927, respectively. These results underscore the potential of the DRMNV2/IFHO model as a valuable tool for improving the accuracy and efficiency of DR diagnosis. Nevertheless, additional validation and testing on larger datasets are required to verify the model's effectiveness and robustness in real-world clinical scenarios.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.